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Abstract 1 
Background: Diarrhoea in children is a common disease; understanding the incidence of causative 2 
viruses can aid infection control and vaccine development.  3 
Objectives: Describe the incidence and characteristics of gastroenteric viruses including  norovirus 4 
genotypes in a paediatric hospital cohort. 5 
Study Design: Norovirus, adenovirus, sapovirus, astrovirus, rotavirus qPCR and norovirus genotyping 6 
results for all stool specimens (n = 4,786; 1,393 patients) at a UK paediatric tertiary referral hospital 7 
June 2014– July 2015.  8 
Results and Discussion: 24% (329/1393) of patients were positive for a GI virus; the majority were 9 
positive for norovirus (44%, 144/329) or adenovirus (44%, 146/329). The overall incidence of 10 
rotavirus (2%) is reduced compared to pre-vaccination studies; however the incidence of other GI 11 
viruses has not increased. Norovirus infections had a significantly higher virus burden compared to 12 
other GI viruses (P ≤0.03); sapovirus infections had the lowest viral burden.  13 
The number of norovirus cases per month did not follow the typical winter seasonal trend of 14 
nationally reported outbreaks. The number of cases per month correlates with the number of 15 
hospital admissions (R = 0.703, P = 0.011); the number of admissions accounts for 50% of the 16 
variability in number of cases per month. The breadth of genotypes seen (48% non-GII.4), suggests a 17 
community source for many norovirus infections and has implications for vaccine development. 18 
All GI viruses caused chronic infections, with the majority (50–100%) in immunocompromised 19 
patients. Incidence or duration of infection in chronic norovirus infections did not differ between 20 
genotypes, suggesting host-mediated susceptibility.  21 
Keywords: Viral gastroenteritis, paediatric, polymerase chain reaction, PCR, norovirus, genotypes22 
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Background 23 
In European children under five years, there are an estimated four episodes of diarrhoea per child 24 
per year [1]; norovirus is the leading causative agent in children [2]. Norovirus is highly transmissible 25 
thus is associated with outbreaks of diarrhoea and vomiting in enclosed settings such as cruise ships, 26 
schools and in particular healthcare institutions. The morbidity associated with infections in 27 
immunocompetent individuals is limited, however the financial burden to healthcare settings is 28 
considerable; in the UK acute gastroenteritis is estimated to cost £115 million per year, 63% of which 29 
is attributable to norovirus [3]. Outbreaks in healthcare settings typically follow a characteristic 30 
winter peak, although this is not mirrored in community outbreaks [4].  31 
Norovirus is a single stranded RNA virus belonging to the calicivirus family. The genome is 7.5 kb, 32 
comprised of three open reading frames; ORF1, ORF2 and ORF3 coding for a non-structural 33 
polyprotein, major and minor capsid proteins, respectively. There are five genogroups (GI –GV) of 34 
which GI, GII and to a lesser extend GIV infect humans. Each genogroup is further classified into 35 
genotypes; GI.1–9 and GII.1–21 based on capsid and/or polymerase gene sequences [5]. Outbreaks 36 
worldwide have been dominated by GII.4 since the mid-1990s [6]. 37 
Objectives 38 
We describe the incidence of gastroenteric viruses in a paediatric UK hospital, with extended 39 
analysis of norovirus genotypes, seasonality and PCR Ct values.  Understanding the molecular 40 
epidemiology of viral gastroenteritis in children will contribute to improving infection control 41 
practices and vaccine development.  42 
Study Design 43 
Sampled population  44 
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Great Ormond Street Hospital is a large tertiary referral paediatric hospital in the UK. The hospital 45 
does not have an accident and emergency department therefore acute gastroenteritis is not the 46 
primary reason for admission. As part of the infection control screening policy at GOSH, all children 47 
are tested for gastrointestinal viruses on admission for inpatient stay, regardless of whether they are 48 
symptomatic or asymptomatic. Patients with a positive stool virus are followed up weekly until they 49 
become negative, however, patients with underlying immunodeficiency are tested weekly and 50 
thereafter at outpatient appointments irrespectively of whether they have previously been positive 51 
for a stool virus.  Any child who develops gastrointestinal symptoms during their inpatient stay or in 52 
outpatients is also tested. Between 1/7/2014 and 30/6/2015 a total of 4,786 stool samples from 53 
1,393 patients (8% outpatients) at Great Ormond Street Hospital for Children, UK, were tested 54 
during routine diagnostic analyses for the presence of gastroenteric viruses (Table 1). 1–46 samples 55 
were tested per patient (median 1) (Supplementary Figure 1). 56 
 PCR results and accompanying clinical data for this study were exported retrospectively from the 57 
laboratory information system. Detection of more than one virus during the study period was 58 
treated as an independent episode in the analysis. 59 
Detection of gastroenteric viruses by real-time PCR 60 
All stool samples were tested by real-time PCR for the presence of norovirus, rotavirus, adenovirus, 61 
astrovirus and sapovirus (supplementary methods). 62 
Norovirus genotyping 63 
The first norovirus positive stool from each patient was genotyped by PCR amplification and capillary 64 
sequencing of the capsid shell domain (supplementary methods). Eleven norovirus positive samples 65 
had insufficient residual volume for genotyping and were excluded from analysis.  66 
National norovirus genotyping data 67 
4 
 
The number of norovirus outbreaks reported nationally to Public Health England (PHE) and the 68 
proportion of each genotype for these incidences was provided by the Virus Reference Department 69 
(VRD), PHE, from their national surveillance data. 70 
Rotavirus vaccine detection 71 
Rotavirus positive specimens were genotyped by the PHE VRD, and GIP8 positives confirmed as 72 
vaccine or wildtype by sequencing the genes encoding VP4 and VP7.  73 
Categorisation of patients 74 
The clinical specialty of each patient was assigned based on the clinical specialty of the ward to 75 
which they were admitted at the time of specimen collection. Immunodeficiency patients consisted 76 
of specialties associated with profound immunodeficiency; bone marrow transplant, oncology, 77 
haematology and immunology specialties. Medical patients consisted of respiratory medicine, 78 
cardiac medicine, renal medicine, intensive care, neurology, dermatology, rheumatology, ear nose 79 
and throat and ophthalmology. It is likely that some patients in the medical category will have some 80 
degree of suppressed immunity.  81 
Norovirus infections detected less than 48 hours after admission to hospital were considered 82 
positive on admission (POA); detection more than two days after admission was considered a 83 
hospital acquired infection (HAI). Since many of the patients at GOSH have complex medical 84 
histories, many of them have previously been admitted to local hospitals or had several outpatient 85 
visits prior to admission at GOSH, therefore earlier acquisition of infection in another healthcare 86 
facility cannot be excluded. 87 
Infections that were detected for longer than one month were considered chronic infections; less 88 
than one month were acute.  89 
Statistical analysis 90 
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Statistical analysis was performed using IBM SPSS Statistics v23 (supplementary methods). 91 
Results 92 
Prevalence of gastroenteric viruses 93 
Twenty-four percent (329/1393) of all patients tested in the twelve month period were positive for a 94 
gastroenteric virus, among which norovirus and adenovirus predominated with 144 and 146 95 
episodes each over the 12 month period, each constituting 44% of all viral gastrointestinal infections 96 
(Table 2). 97 
Forty-four of the 329 infections (13%) were mixed infections with more than one virus detected 98 
(Table 2). The predominant mixed infections (23 /44, 52%) were norovirus and adenovirus, followed 99 
by norovirus and sapovirus (7/44, 16%) and adenovirus and sapovirus (6/44, 14%). Rotavirus was 100 
least frequently detected as part of a mixed infection (5/44, 11%). An equal number of mixed 101 
infections were from medical and immunocompromised patients; 16/44 (36%) each. Given that only 102 
19% of patients tested were in the 'immunocompromised' category, this suggests mixed infections 103 
are likely to be more frequently associated with immune dysfunction.  104 
The median age of patients with a rotavirus infection, 0.7 years, was significantly younger than other 105 
infections with a median age of 2–3 years (P ≤0.015, Supplementary Figure 2).  106 
Norovirus infections had a significantly higher virus burden, median Ct 23, compared to other 107 
infections (P ≤ 0.03, Figure 1a). Sapovirus infections had the lowest viral burden; median Ct 35.  108 
Rotavirus vaccine-derived infections 109 
Four rotavirus positive patients had insufficient residual specimen for genotyping, thus 29 of 33 110 
samples were genotyped.  28% (8/29) of rotavirus infections were identified as vaccine strain.  111 
Prevalence of norovirus genotypes 112 
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Eighty-seven percent (117/133) of norovirus infections were genogroup II (GII), which had a 113 
significantly higher virus burden (median Ct 22) compared to genogroup I (GI) infections (median Ct 114 
28)(P = 0.004, Figure 1b).  115 
The majority of norovirus infections were GII.4 and GII.3; 52% and 26%, respectively (63/133 and 116 
32/133), with the remaining 22% (38/133) identified as GI.1, GI.2, GI.3, GI.4, GII.1, GII.2, GII.6 or 117 
GII.17 (Figure 2). Eleven samples (8%) could not be amplified by PCR; these had a significantly lower 118 
viral burden compared to other samples (median Ct 35 and 22 for failed and successful typing, 119 
respectively, P ≤ 0.001).  120 
Norovirus seasonality 121 
The proportion of norovirus genotypes each month in our paediatric population is not the same as 122 
those seen in nationally reported outbreaks, primarily attributable to the increased proportion of 123 
GII.3 in our population (Figure 3). A peak in incidence of GI.3 in nationally reported outbreaks from 124 
August to November 2014 is followed by a similar peak in our paediatric population from September 125 
to December 2014. Conversely, a peak in GII.6 episodes in our population from March to June 2015 126 
is not seen in nationally reported outbreaks (Figure 3).  127 
The overall number of norovirus cases per month in our population does not follow the typical 128 
winter peak seen in national outbreaks (Figure 3). Instead it was noted that in our population the 129 
number of cases of norovirus per month follows a similar trend to the number of hospital 130 
admissions, including outpatient visits and transfer between wards (Figure 4). There is a significant 131 
positive correlation between the number of admissions and number of norovirus cases per month (R 132 
= 0.703, P = 0.011). This suggests that the number of hospital admissions accounts for 50% of the 133 
variability in number of norovirus cases (R2 = 0.494). Based on the Poisson regression coefficient 134 
(𝑦 = −1.447 + 0.001𝑥) it is estimated that one case of norovirus occurs for every 100 admissions 135 
(95% CI 0.000–0.002, P = 0.002). 136 
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Seasonality of other viruses 137 
Similarly to norovirus, adenovirus showed a summer peak in new infections. Conversely rotavirus 138 
infections had a spring peak, sapovirus peaked in winter and spring and astrovirus showed no 139 
distinct seasonal trends (Supplementary Figure 3).  140 
Hospital and community acquired norovirus infections 141 
Infections acquired before admission (POA) include a greater range of genotypes, with hospital 142 
acquired infections (HAI) showing a higher proportion of GII.4 infections (40% and 68%, respectively; 143 
Supplementary Figure 4); however this difference is not significant (P = 0.062). 144 
Norovirus in clinical specialties 145 
The incidence of norovirus infection is higher in immunocompromised compared to surgical or 146 
medical patients; 19% (51/270) of immunocompromised patients tested were found to be norovirus 147 
positive compared to 5% (10/202) and 7% (57/803) of surgical and medical patients.   148 
There was no significant difference in the norovirus PCR Ct values between immunocompromised 149 
and non-immunocompromised patients (median Ct 23 and 24, respectively; P=0.226). 150 
Chronic infections 151 
Norovirus had the highest rate of chronic infections (38/144, 25%); adenovirus, rotavirus and 152 
sapovirus had similar rates whilst astrovirus had the fewest (1/18, 6%) (Table 2, Supplementary 153 
Figure 5a). With the exception of sapovirus, in which chronic infections occurred equally in 154 
immunocompromised and medical clinical specialties, the majority (67–100%) of chronic infections 155 
were in patients from immunocompromised clinical specialties (Supplementary Figure 5b). 156 
There was no difference in proportion of chronic patients between the different norovirus 157 
genotypes (Supplementary Figure 6, P = 0.801). The median duration of infection in chronically 158 
infected patients was 5 months (range 1–21 months). 159 
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Discussion 160 
We present the incidence of viral gastrointestinal infections and the prevalence of norovirus 161 
genotypes in a large cohort of 1,393 paediatric patients in a tertiary referral hospital over a 12 162 
month period, which is dominated by norovirus and adenovirus infections. This is similar to previous 163 
reports of UK hospitalised children in which norovirus and adenovirus were detected in 15–16% and 164 
14–15% of cases, respectively[7]. 165 
Following the introduction of the rotavirus vaccine to the UK childhood vaccination programme in 166 
July 2013 the incidence of rotavirus infections has reduced by 67%[8], which is reflected in the low 167 
incidence of 2% reported in this study; an earlier study of hospitalised UK children reported a 31% 168 
rotavirus positive rate[7]. Whilst the rate of rotavirus positive patients is reduced compared to the 169 
pre-vaccination UK study [7] the rate of detection of norovirus, adenovirus, sapovirus and astrovirus 170 
is similar; consequently the overall positivity rate for gastrointestinal viruses is lower than previously 171 
reported; 23% in this study compared to 53% reported previously[7]. This suggests that other 172 
gastrointestinal viruses have not increased in prevalence to replace rotavirus infections.  173 
Unexpectedly, the overall incidence of norovirus does not follow the characteristic seasonal trend 174 
seen in national outbreaks. Instead the number of infections per month strongly correlates with the 175 
number of hospital admissions, accounting for 50% of the variability in norovirus incidence. Our 176 
results suggest that the incidence of norovirus in a tertiary children’s hospital is driven by traffic 177 
through the hospital, rather seasonal outbreaks. The breadth of genotypes seen in this study, more 178 
commonly seen in community cohorts compared to hospitals, backs this hypothesis; patients 179 
presenting to primary healthcare facilities, such as GP practices, reportedly have a lower proportion 180 
of GII.4 infections; 54% compared to 91% of hospital infections are GII.4 [9]. The true distribution of 181 
norovirus genotypes in the community is not known since all genotyping studies to date are based 182 
on patients presenting to healthcare facilities thus introducing a presentation bias. Genotyping of 183 
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norovirus infections in unbiased community cohorts is needed in order to determine whether 184 
infections caused by a breadth of genotypes are a true reflection of the community. 185 
In our cohort a quarter (26%) of norovirus infections were caused by GII.3, which has previously 186 
been described in varying proportions in UK paediatric cohorts, from 0–20%[10]. This is different to 187 
adult cohorts, in which outbreaks are largely dominated by GII.4[9]. Our data supports the notion 188 
that GII.3 is more frequently associated with children; however the reason for this is unknown. We 189 
speculate the reason could be immunity to GII.3 in the adult population following childhood 190 
infection, differences in receptor binding between children and adults or lower transmissibility 191 
compared to GII.4 resulting in fewer associated outbreaks and reporting bias.  192 
All patients in this study have been categorised by clinical specialty; this was based on the ward to 193 
which they were admitted at the time of specimen collection. It is clear that immunocompromised 194 
patients are over-represented among patients with norovirus infection; 19% of 195 
immunocompromised patients were found to be norovirus positive, compared to just 5% and 7% of 196 
surgical and medical patients, respectively.  Previous studies in smaller cohorts of 47 and 116 197 
immunocompromised patients have reported incidence of norovirus as 23% and 22%, respectively 198 
[11, 12] which suggests the categorisation of patients into clinical specialties in this study is reliable 199 
and that our larger cohort of 270 immunocompromised patients corroborates earlier findings.  200 
Norovirus, adenovirus, rotavirus and sapovirus show a similar rate of chronic infections (15–26% PCR 201 
positive >1 month), with the highest rate in norovirus and the lowest (6%) in astrovirus; the vast 202 
majority of chronic infections were in immunocompromised patients. Chronic norovirus infections in 203 
immunocompromised patients is a recognised cause of morbidity, in whom a bi-phasic illness 204 
develops [13] with an initial acute phase followed by  a second chronic phase with viral shedding and 205 
diarrhoea lasting weeks to years. The consequence of chronic norovirus infection can be 206 
dehydration, malnutrition, dysfunction of intestinal barrier [14], dramatic weight loss [15], a 207 
requirement for nutritional support [16] and, in extreme cases, death [15, 17]. Immunocompromised 208 
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patients in this study do not show a higher norovirus viral burden or difference in genotypes; 209 
suggesting the higher chronicity in immunocompromised patients is host, not virus, mediated. 210 
The linear relationship between viral load and PCR Ct value makes Ct values a good semi-211 
quantitative indicator of viral burden, with a difference of 3 Ct values equating to a log difference in 212 
viral load[18]. However, despite efforts to standardise stool volume in RNA extraction, differences in 213 
stool consistency make the input variable which may falsely indicate a higher or lower viral burden 214 
when comparing samples. Consequently small differences in viral burden, such as a two-fold 215 
difference estimated by a difference in Ct value of 1, are unlikely to be reliable when comparing 216 
stool samples. However major differences in viral burden, such as a log, are likely to be reliable since 217 
the input volume, whilst variable, is not expected to vary by such extremes.   218 
We report the incidence of gastroenteric viruses in a large observational cohort of paediatric 219 
patients in a UK hospital following the implementation of routine rotavirus vaccination, showing 220 
rotavirus incidence of just 2%. All viruses are shown to establish chronicity, primarily in 221 
immunocompromised patients. We observe that new infections are not driven by seasonal trends, 222 
which may be specific to our population but has been reported in community cohorts[4]. The high 223 
proportion of non-GII.4 infections may have implications for vaccine development. 224 
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